RxDoctor Payments Data

Abed Jandali, MD

Surgery · Green Island, NYNPI 1003918277

Payments from drug & device makers

$3,108in general payments, 2019–2025

Across 72 payments — averaging $43.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$481
  • Sanofi$185
  • Novo Nordisk$175
  • Boehringer Ingelheim$153
  • Merck$62
  • plus $57 from 3 others

What the payments were for

  • Consulting fees$301%
  • Speaking & faculty fees$1856%
  • Food & beverage$2,89393%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca37$1,995
GSK20$481
Sanofi1$185
Novo Nordisk4$175
Boehringer Ingelheim3$153
Merck4$62
Medtronic1$30
Lilly USA, LLC1$14
AbbVie1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,108 in reported general payments places this provider in the 60th percentile of 1,596 surgery providers in New York.

See all surgery providers in New York

Medicare billing

Part B allowed, 2024
$13,577
Medicare patients
24
Services billed
107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin15$9,558
SteglatroErtugliflozin Pidolate11$3,865
Albuterol Sulfate HfaAlbuterol Sulfate32$852
Atorvastatin Calcium65$575
Nifedipine ErNifedipine29$491
Rosuvastatin Calcium33$460
Omeprazole32$369
Metoprolol Succinate30$314
Levothyroxine Sodium16$297
Losartan Potassium24$255
Lisinopril57$250
ClopidogrelClopidogrel Bisulfate11$248
Simvastatin13$230
Ezetimibe14$230
Pantoprazole Sodium25$222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$153$9,55815 claims
MerckSteglatro$62$3,86511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,596 surgery providers in New York.

Other surgery in Green Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →